Corient Private Wealth LLC Sells 13,886 Shares of Edwards Lifesciences Co. (NYSE:EW)

Corient Private Wealth LLC lowered its position in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 12.9% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 94,066 shares of the medical research company's stock after selling 13,886 shares during the period. Corient Private Wealth LLC's holdings in Edwards Lifesciences were worth $6,963,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of EW. Natixis Advisors LLC grew its position in Edwards Lifesciences by 51.9% in the 4th quarter. Natixis Advisors LLC now owns 288,443 shares of the medical research company's stock valued at $21,353,000 after buying an additional 98,554 shares in the last quarter. Frank Rimerman Advisors LLC boosted its holdings in shares of Edwards Lifesciences by 25.9% in the fourth quarter. Frank Rimerman Advisors LLC now owns 6,766 shares of the medical research company's stock valued at $501,000 after acquiring an additional 1,392 shares in the last quarter. Van Strum & Towne Inc. increased its stake in shares of Edwards Lifesciences by 4.8% during the fourth quarter. Van Strum & Towne Inc. now owns 7,134 shares of the medical research company's stock valued at $528,000 after acquiring an additional 326 shares during the period. Midwest Professional Planners LTD. raised its holdings in Edwards Lifesciences by 6.8% during the fourth quarter. Midwest Professional Planners LTD. now owns 36,784 shares of the medical research company's stock worth $2,723,000 after purchasing an additional 2,343 shares in the last quarter. Finally, Postrock Partners LLC acquired a new stake in Edwards Lifesciences in the fourth quarter worth approximately $380,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Edwards Lifesciences Stock Performance

Shares of EW stock traded down $0.06 during trading on Tuesday, reaching $71.29. The company had a trading volume of 6,112,449 shares, compared to its average volume of 4,612,307. The company has a market capitalization of $41.91 billion, a PE ratio of 10.23, a PEG ratio of 4.82 and a beta of 1.12. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The firm's 50 day simple moving average is $71.43 and its two-hundred day simple moving average is $70.42. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $96.12.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. Sell-side analysts forecast that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on EW shares. Citigroup boosted their price target on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the stock a "buy" rating in a research report on Wednesday, December 11th. Royal Bank of Canada reiterated an "outperform" rating and set a $85.00 price objective on shares of Edwards Lifesciences in a research report on Wednesday, February 12th. Evercore ISI reduced their target price on Edwards Lifesciences from $75.00 to $73.00 and set an "in-line" rating for the company in a report on Wednesday, February 12th. Stifel Nicolaus raised Edwards Lifesciences from a "hold" rating to a "buy" rating and lifted their price target for the stock from $75.00 to $90.00 in a research note on Thursday, January 30th. Finally, Piper Sandler upped their price target on shares of Edwards Lifesciences from $70.00 to $73.00 and gave the company a "neutral" rating in a research report on Wednesday, February 12th. One research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $79.95.

Insiders Place Their Bets

In related news, VP Daniel J. Lippis sold 500 shares of the business's stock in a transaction on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total transaction of $34,380.00. Following the transaction, the vice president now owns 23,189 shares of the company's stock, valued at approximately $1,594,475.64. The trade was a 2.11 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 9,500 shares of the stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $67.96, for a total transaction of $645,620.00. Following the completion of the sale, the vice president now directly owns 46,936 shares of the company's stock, valued at approximately $3,189,770.56. This trade represents a 16.83 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 51,303 shares of company stock valued at $3,715,776 in the last three months. Company insiders own 1.29% of the company's stock.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.